Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New psoriasis pill shows promise in early trial

NCT ID NCT05357755

Disease control Sponsor: Janssen Research & Development, LLC Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested an oral tablet called JNJ-77242113 in 90 adults with moderate-to-severe plaque psoriasis. Participants were randomly assigned to receive the drug or a placebo for 16 weeks. The main goal was to see if the drug could improve psoriasis symptoms by at least 75% compared to placebo.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
JNJ-77242113 (oral tablet)
What this could lead to
If successful, this could lead to a new oral treatment option for people with moderate-to-severe plaque psoriasis, potentially offering an alternative to injections or topical creams.
What could go wrong
This is an early Phase 2a trial with only 90 participants, so results may not apply to everyone. The drug may not work better than placebo, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

90 people

The number who actually took part.

Started

Jun 2022

Finished

Apr 2023

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participant has a diagnosis of plaque psoriasis, with or without psoriatic arthritis, for at least 26 weeks prior to the first administration of study intervention * Participant has a total Body Surface Area (BSA) greater than or equal to (\>=) 10 percentage (%) at screening and baseline * Participant has a total Psoriasis Area and Severity Index (PASI) \>= 12 at screening and baseline * Participant has a total Investigator's Global Assessment (IGA) \>= 3 at screening and baseline * Participant be a candidate for phototherapy or systemic treatment for plaque psoriasis Exclusion Criteria: * Participant has a nonplaque form of psoriasis (for example, erythrodermic, guttate, or pustular) * Participant has current drug-induced psoriasis (for example, a new onset of psoriasis or an exacerbation of psoriasis from beta blockers, calcium channel blockers, or lithium) * Participant have previously received any other therapeutic agent directly targeted to interleukin 23 (including but not limited to guselkumab, tildrakizumab, or risankizumab) * Participant has received any therapeutic agent directly targeted to interleukin 17 (IL-17), interleukin 17 receptor (IL-17R) or interleukin 12/23 (IL-12/23) (including but not limited to secukinumab, ixekizumab, brodalumab, or ustekinumab) or has received biological therapy targeting tumor necrosis factor (TNF) (including, but not limited to adalimumab, infliximab, or etanercept) within 12 weeks or 5 half-lives, whichever is longer, of the first administration of study intervention * Participant has received proton pump inhibitors (including but not limited to omeprazole, esomeprazole, lansoprazole, rabeprazole, pantoprazole, dexlansoprazole, or zegerid) within 1 week of first administration of study intervention

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Plaque psoriasis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Plaque psoriasis

Contacts and locations

Locations

  • ActivMed Practices and Research

    Beverly, Massachusetts, 01915, United States

  • ActivMed Practices and Research

    Portsmouth, New Hampshire, 03801, United States

  • Arlington Center for Dermatology

    Arlington, Texas, 76011, United States

  • CHRU Brest - Hopital Morvan

    Brest, 29200, France

  • CHU de Grenoble Hopital Albert Michallon

    La Tronche, 38700, France

  • CHU de Nice Hopital de l Archet

    Nice, 06200, France

  • Centrum Terapii Wspolczesnej J M Jasnorzewska Spolka Komandytowo Akcyjna

    Lodz, 90-338, Poland

  • DermEdge Research

    Mississauga, Ontario, L4Y 4C5, Canada

  • Dermatology Research Institute Inc

    Calgary, Alberta, T2J 7E1, Canada

  • Dermatology Specialists

    Louisville, Kentucky, 40241, United States

  • Epiphany Dermatology of Kansas, LLC

    Overland Park, Kansas, 66210, United States

  • Hautarztpraxis

    Bramsche, 49565, Germany

  • Health Concepts

    Rapid City, South Dakota, 57702, United States

  • Hosp. Univ. San Cecilio

    Granada, 18016, Spain

  • Hosp. Univ. de Cruces

    Barakaldo, 48902, Spain

  • Hosp. Virgen Macarena

    Seville, 41009, Spain

  • Lawrence J Green MD LLC

    Rockville, Maryland, 20850, United States

  • Lynderm Research Inc.

    Markham, Ontario, L3P 1X2, Canada

  • Northshore University Healthsystem

    Skokie, Illinois, 60077, United States

  • Polyclinique de Courlancy

    Reims, 51100, France

  • Privatpraxis Dr. Hilton & Partner

    Düsseldorf, 40212, Germany

  • Specderm Poznanska sp j

    Bialystok, 15 375, Poland

  • Specjalistyczny gabinet dermatologiczny Aplikacyjno Badawczy Marek Brzewski Pawel Brzewski Spolka Cywilna

    Krakow, 30 002, Poland

  • Stoll Dermatology

    Beverly Hills, California, 90212, United States

  • The Guenther Dermatology Research Centre

    London, Ontario, N6A 3H7, Canada

  • The Pennsylvania Centre for Dermatology, LLC

    Exton, Pennsylvania, 19341, United States

  • Toronto Research Centre

    Toronto, Ontario, M3H 5Y8, Canada

  • Unity Clinical Research

    Oklahoma City, Oklahoma, 73118, United States

  • Universitaetsmedizin Rostock

    Rostock, 18057, Germany

  • Universitatsklinikum Carl Gustav Carus Dresden

    Dresden, 01307, Germany

  • Universitatsklinikum Frankfurt

    Frankfurt am Main, 60590, Germany

  • Universitatsklinikum Munster

    Münster, 48149, Germany

  • Universitatsklinikum Schleswig Holstein Campus Lubeck

    Lübeck, 23538, Germany

  • Windsor Dermatology, PC

    East Windsor, New Jersey, 08520, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.